# Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

> **NCT04440358** · PHASE1,PHASE2 · COMPLETED · sponsor: **InSightec** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DEVICE:** Exablate BBBD
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04440358
- **Lead sponsor:** InSightec
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-13
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440358, "Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04440358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*